Business Context and Reporting Period
This Form 6-K filing by Phoenix Asia Holdings Ltd covers the month of May 2026, specifically dated May 4, 2026. The filing discloses the entry into a material definitive agreement and the issuance of a convertible promissory note. The Company is a foreign private issuer based in Hong Kong.
Key Financial Metrics and Transactions
- Stock Acquisition Agreement: The Company agreed to acquire 100% of ACEA Pharma, Inc. (Target Company) in exchange for 100,000,000 newly-issued ordinary shares. The agreed value of the transaction is $1,000,000,000.00.
- Convertible Promissory Note: The Company issued a non-interest-bearing convertible promissory note with a principal sum of $20,000,000.00 to Phoenix Prosperity Investment Limited (controlling shareholder). The note matures in three years and is convertible at $10.00 per share.
- Revenue, Profit, and Cash Flow: The filing text does not provide a clear value for current period revenue, profit, cash flow, margins, or existing debt levels. This report focuses on transactional events rather than periodic financial performance.
Material Changes and Transaction Details
The primary material change is the proposed acquisition of ACEA Pharma, Inc., a clinical-stage pharmaceutical company with a portfolio addressing cancer, autoimmune diseases, and Covid-19. This represents a significant strategic shift or expansion into the biopharmaceutical sector. The transaction involves a substantial equity issuance (100 million shares) valued at $1 billion, which will significantly dilute existing shareholders upon closing.
Guidance, Outlook, Risks, and Contingencies
- Closing Conditions: The acquisition is expected to close in the second quarter of 2026, subject to customary conditions.
- Regulatory Approvals: Closing is contingent upon the expiration of waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act and receipt of necessary Nasdaq approvals (including reviews for reverse merger or change of control).
- Forward-Looking Statements: The filing includes projections regarding the timing and completion of the transaction and the conversion of the note. Management explicitly states these are not guarantees and involve risks that could cause actual results to differ materially.
- Unusual Items: The $20 million note was issued as consideration for advisory and transaction support services provided by the controlling shareholder.
Investor Verification Checklist
- Verify the final valuation of ACEA Pharma, Inc. and the rationale for the $1 billion price tag.
- Confirm the status of Nasdaq approval regarding the potential reverse merger or change of control review.
- Assess the dilution impact of issuing 100,000,000 new shares on existing shareholders.
- Review the specific terms of the advisory services provided by the controlling shareholder to justify the $20 million convertible note.
- Monitor the clinical stage and pipeline status of ACEA Pharma's products in cancer, autoimmune disease, and Covid-19.